We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients. (SORT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01295021
First Posted: February 14, 2011
Last Update Posted: June 10, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
The purpose of this NIS is to assess the prevalence of sympathetic overactivity in patients with newly diagnosed essential hypertension.

Condition
Essential Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Non Interventional, Cross Sectional, Study on the Prevalence of Sympathetic Overactivity in Hypertensive Patients.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Prevalence of SO in newly diagnosed hypertensive patients [ Time Frame: Visit 1-3: heart rate & Blood pressure, treatment presribed by physician. The interval between visit 1 and visit 2 is upto 4 weeks and interval between visit 2 & visit 3 is upto 4 weeks depending on Investigators discretion. ]

Secondary Outcome Measures:
  • Association of SO and heart rate. [ Time Frame: Visits 1-3 ]
  • Subjective symptoms noticed by the doctor. [ Time Frame: 1st visit ]
  • To record the drugs used in the treatment of patients diagnosed with hypertension. [ Time Frame: Visits 1-3 ]

Enrollment: 1514
Study Start Date: February 2011
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Detailed Description:
MC MD
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary hypertensive patients
Criteria

Inclusion Criteria:

  • Newly diagnosed essential hypertension patients will be eligible for the study.
  • Average of two or more systolic BP readings ≥ 140mmHg or diastolic BP readings ≥ 90mmHg

Exclusion Criteria:

  • History of coronary artery disease
  • History of diabetes
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01295021


  Show 99 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Dr T.N.C. Padmanabhan Dr. Padmanabhan Heart Clinic
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01295021     History of Changes
Other Study ID Numbers: NIS-CIN-DUM-2010/2
First Submitted: February 3, 2011
First Posted: February 14, 2011
Last Update Posted: June 10, 2013
Last Verified: June 2013

Keywords provided by AstraZeneca:
The prevalence of sympathetic overactivity in hypertensive patients.